Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

β1-Adrenoreceptor Polymorphisms and Blood Pressure: 49S Variant Increases Plasma Renin But Not Blood Pressure in Hypertensive Patients.

Sandilands AJ, O'Shaughnessy KM.

Am J Hypertens. 2019 Apr 22;32(5):447-451. doi: 10.1093/ajh/hpz019.

2.

The matrix proteins aggrecan and fibulin-1 play a key role in determining aortic stiffness.

Yasmin, Maskari RA, McEniery CM, Cleary SE, Li Y, Siew K, Figg NL, Khir AW, Cockcroft JR, Wilkinson IB, O'Shaughnessy KM.

Sci Rep. 2018 Jun 4;8(1):8550. doi: 10.1038/s41598-018-25851-5.

3.

Targeted disruption of the Kcnj5 gene in the female mouse lowers aldosterone levels.

Hardege I, Long L, Al Maskari R, Figg N, O'Shaughnessy KM.

Clin Sci (Lond). 2018 Jan 16;132(1):145-156. doi: 10.1042/CS20171285. Print 2018 Jan 16.

4.

Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia.

Ware JS, Wain LV, Channavajjhala SK, Jackson VE, Edwards E, Lu R, Siew K, Jia W, Shrine N, Kinnear S, Jalland M, Henry AP, Clayton J, O'Shaughnessy KM, Tobin MD, Schuster VL, Cook S, Hall IP, Glover M.

J Clin Invest. 2017 Sep 1;127(9):3367-3374. doi: 10.1172/JCI89812. Epub 2017 Aug 7.

5.

WNK signalling pathways in blood pressure regulation.

Murthy M, Kurz T, O'Shaughnessy KM.

Cell Mol Life Sci. 2017 Apr;74(7):1261-1280. doi: 10.1007/s00018-016-2402-z. Epub 2016 Nov 4. Review.

6.

A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and striking increase in aortic TGFB1/2 expression.

Al Maskari R, Yasmin, Cleary S, Figg N, Mehta S, Rassl D, Wilkinson I, O'Shaughnessy KM.

Eur J Hum Genet. 2016 Jan;25(1):157-160. doi: 10.1038/ejhg.2016.143. Epub 2016 Oct 26.

7.

ROMK expression remains unaltered in a mouse model of familial hyperkalemic hypertension caused by the CUL3Δ403-459 mutation.

Murthy M, Kurz T, O'Shaughnessy KM.

Physiol Rep. 2016 Jul;4(13). pii: e12850. doi: 10.14814/phy2.12850.

8.

Authors' reply to Ninan and Millar and Abou-saleh.

O'Shaughnessy KM, Kennard L.

BMJ. 2016 Apr 26;353:i2253. doi: 10.1136/bmj.i2253. No abstract available.

PMID:
27118732
9.

Treating hypertension in patients with medical comorbidities.

Kennard L, O'Shaughnessy KM.

BMJ. 2016 Feb 16;352:i101. doi: 10.1136/bmj.i101. No abstract available.

PMID:
26884124
10.

Novel Insertion Mutation in KCNJ5 Channel Produces Constitutive Aldosterone Release From H295R Cells.

Hardege I, Xu S, Gordon RD, Thompson AJ, Figg N, Stowasser M, Murrell-Lagnado R, O'Shaughnessy KM.

Mol Endocrinol. 2015 Oct;29(10):1522-30. doi: 10.1210/me.2015-1195. Epub 2015 Sep 4.

11.

Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia.

Schumacher FR, Siew K, Zhang J, Johnson C, Wood N, Cleary SE, Al Maskari RS, Ferryman JT, Hardege I, Yasmin, Figg NL, Enchev R, Knebel A, O'Shaughnessy KM, Kurz T.

EMBO Mol Med. 2015 Oct;7(10):1285-306. doi: 10.15252/emmm.201505444.

12.

Critical role of the SPAK protein kinase CCT domain in controlling blood pressure.

Zhang J, Siew K, Macartney T, O'Shaughnessy KM, Alessi DR.

Hum Mol Genet. 2015 Aug 15;24(16):4545-58. doi: 10.1093/hmg/ddv185. Epub 2015 May 20.

13.

Gordon Syndrome: a continuing story.

O'Shaughnessy KM.

Pediatr Nephrol. 2015 Nov;30(11):1903-8. doi: 10.1007/s00467-014-2956-7. Epub 2014 Dec 11. Review.

PMID:
25503323
14.

A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?

Barber J, McKeever TM, McDowell SE, Clayton JA, Ferner RE, Gordon RD, Stowasser M, O'Shaughnessy KM, Hall IP, Glover M.

Br J Clin Pharmacol. 2015 Apr;79(4):566-77. doi: 10.1111/bcp.12499.

15.

Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism.

Murthy M, Xu S, Massimo G, Wolley M, Gordon RD, Stowasser M, O'Shaughnessy KM.

Hypertension. 2014 Apr;63(4):783-9. doi: 10.1161/HYPERTENSIONAHA.113.02234. Epub 2014 Jan 13.

PMID:
24420545
16.

Detection of mutations in KLHL3 and CUL3 in families with FHHt (familial hyperkalaemic hypertension or Gordon's syndrome).

Glover M, Ware JS, Henry A, Wolley M, Walsh R, Wain LV, Xu S, Van't Hoff WG, Tobin MD, Hall IP, Cook S, Gordon RD, Stowasser M, O'Shaughnessy KM.

Clin Sci (Lond). 2014 May;126(10):721-6. doi: 10.1042/CS20130326.

17.

Molecular insights from dysregulation of the thiazide-sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and thiazide-induced hyponatraemia.

Glover M, O'Shaughnessy KM.

Clin Exp Pharmacol Physiol. 2013 Dec;40(12):876-84. doi: 10.1111/1440-1681.12115. Review.

PMID:
23683032
18.

Extrarenal roles of the with-no-lysine[K] kinases (WNKs).

Siew K, O'Shaughnessy KM.

Clin Exp Pharmacol Physiol. 2013 Dec;40(12):885-94. doi: 10.1111/1440-1681.12108. Review.

PMID:
23662678
19.

An inducible transgenic mouse model for familial hypertension with hyperkalaemia (Gordon's syndrome or pseudohypoaldosteronism type II).

Chowdhury JA, Liu CH, Zuber AM, O'Shaughnessy KM.

Clin Sci (Lond). 2013 Jun;124(12):701-8. doi: 10.1042/CS20120430.

PMID:
23336180
20.

Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma.

Murthy M, Azizan EA, Brown MJ, O'Shaughnessy KM.

J Hypertens. 2012 Sep;30(9):1827-33. doi: 10.1097/HJH.0b013e328356139f. Erratum in: J Hypertens. 2014 Apr;32(4):948.

PMID:
22743686
21.

Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas.

Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ, O'Shaughnessy KM.

Hypertension. 2012 Mar;59(3):587-91. doi: 10.1161/HYPERTENSIONAHA.111.186239. Epub 2012 Jan 17.

PMID:
22252394
22.

Common genetic variation in the 3'-BCL11B gene desert is associated with carotid-femoral pulse wave velocity and excess cardiovascular disease risk: the AortaGen Consortium.

Mitchell GF, Verwoert GC, Tarasov KV, Isaacs A, Smith AV, Yasmin, Rietzschel ER, Tanaka T, Liu Y, Parsa A, Najjar SS, O'Shaughnessy KM, Sigurdsson S, De Buyzere ML, Larson MG, Sie MP, Andrews JS, Post WS, Mattace-Raso FU, McEniery CM, Eiriksdottir G, Segers P, Vasan RS, van Rijn MJ, Howard TD, McArdle PF, Dehghan A, Jewell ES, Newhouse SJ, Bekaert S, Hamburg NM, Newman AB, Hofman A, Scuteri A, De Bacquer D, Ikram MA, Psaty BM, Fuchsberger C, Olden M, Wain LV, Elliott P, Smith NL, Felix JF, Erdmann J, Vita JA, Sutton-Tyrrell K, Sijbrands EJ, Sanna S, Launer LJ, De Meyer T, Johnson AD, Schut AF, Herrington DM, Rivadeneira F, Uda M, Wilkinson IB, Aspelund T, Gillebert TC, Van Bortel L, Benjamin EJ, Oostra BA, Ding J, Gibson Q, Uitterlinden AG, Abecasis GR, Cockcroft JR, Gudnason V, De Backer GG, Ferrucci L, Harris TB, Shuldiner AR, van Duijn CM, Levy D, Lakatta EG, Witteman JC.

Circ Cardiovasc Genet. 2012 Feb 1;5(1):81-90. doi: 10.1161/CIRCGENETICS.111.959817. Epub 2011 Nov 8.

23.

Role of SPAK and OSR1 signalling in the regulation of NaCl cotransporters.

Mercier-Zuber A, O'Shaughnessy KM.

Curr Opin Nephrol Hypertens. 2011 Sep;20(5):534-40. doi: 10.1097/MNH.0b013e3283484b06. Review.

PMID:
21610494
24.

A Single Amino Acid Substitution Makes WNK4 Susceptible to SB 203580 and SB 202190.

Glover M, Sweeny C, Davis B, O'Shaughnessy KM.

Open Med Chem J. 2010 Sep 3;4:57-61. doi: 10.2174/1874104501004010057.

25.

Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT.

Glover M, Zuber AM, O'Shaughnessy KM.

Cardiovasc Ther. 2011 Feb;29(1):68-76. doi: 10.1111/j.1755-5922.2010.00180.x. Epub 2010 Dec 19. Review.

PMID:
21167012
26.

SPAK and WNK kinases: a new target for blood pressure treatment?

Glover M, O'shaughnessy KM.

Curr Opin Nephrol Hypertens. 2011 Jan;20(1):16-22. doi: 10.1097/MNH.0b013e32834132bc. Review.

PMID:
21088576
27.

The activity of the thiazide-sensitive Na(+)-Cl(-) cotransporter is regulated by protein phosphatase PP4.

Glover M, Mercier Zuber A, Figg N, O'Shaughnessy KM.

Can J Physiol Pharmacol. 2010 Oct;88(10):986-95. doi: 10.1139/y10-080.

PMID:
20962898
28.

Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II.

Carss KJ, Stowasser M, Gordon RD, O'Shaughnessy KM.

J Hum Hypertens. 2011 Sep;25(9):560-4. doi: 10.1038/jhh.2010.93. Epub 2010 Oct 7.

PMID:
20927129
29.

Role of the WNK-activated SPAK kinase in regulating blood pressure.

Rafiqi FH, Zuber AM, Glover M, Richardson C, Fleming S, Jovanović S, Jovanović A, O'Shaughnessy KM, Alessi DR.

EMBO Mol Med. 2010 Feb;2(2):63-75. doi: 10.1002/emmm.200900058.

30.

Primary prevention of CVD: treating hypertension.

Cheriyan J, O'Shaughnessy KM, Brown MJ.

BMJ Clin Evid. 2010 Feb 18;2010. pii: 0214. Review.

31.

Renal and brain isoforms of WNK3 have opposite effects on NCCT expression.

Glover M, Zuber AM, O'Shaughnessy KM.

J Am Soc Nephrol. 2009 Jun;20(6):1314-22. doi: 10.1681/ASN.2008050542. Epub 2009 May 21.

32.

Dissecting complex traits: recent advances in hypertension genomics.

O'Shaughnessy KM.

Genome Med. 2009 Apr 28;1(4):43. doi: 10.1186/gm43.

33.

Expression of the epithelial Na(+) channel and other components of an aldosterone response pathway in human adrenocortical cells.

Burton TJ, Cope G, Wang J, Sim JC, Azizan EA, O'Shaughnessy KM, Brown MJ.

Eur J Pharmacol. 2009 Jun 24;613(1-3):176-81. doi: 10.1016/j.ejphar.2009.04.005. Epub 2009 Apr 14. Erratum in: Eur J Pharmacol. 2009 Sep 1;617(1-3):131.

PMID:
19371736
34.

Both TASK-3 and TREK-1 two-pore loop K channels are expressed in H295R cells and modulate their membrane potential and aldosterone secretion.

Brenner T, O'Shaughnessy KM.

Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1480-6. doi: 10.1152/ajpendo.90652.2008. Epub 2008 Oct 14.

35.

The acidic motif of WNK4 is crucial for its interaction with the K channel ROMK.

Murthy M, Cope G, O'Shaughnessy KM.

Biochem Biophys Res Commun. 2008 Oct 31;375(4):651-4. doi: 10.1016/j.bbrc.2008.08.076. Epub 2008 Aug 26.

PMID:
18755144
36.

Genetics of arterial structure and function: towards new biomarkers for aortic stiffness?

Yasmin, O'Shaughnessy KM.

Clin Sci (Lond). 2008 Jun;114(11):661-77. doi: 10.1042/CS20070369. Review.

PMID:
18442360
37.

Role of diet in hypertension management.

O'Shaughnessy KM.

Curr Hypertens Rep. 2006 Aug;8(4):292-7. Review.

PMID:
16884659
38.

Regulation of the expression of the Na/Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved.

Golbang AP, Cope G, Hamad A, Murthy M, Liu CH, Cuthbert AW, O'shaughnessy KM.

Am J Physiol Renal Physiol. 2006 Dec;291(6):F1369-76. Epub 2006 Jun 20.

39.

WNK1 affects surface expression of the ROMK potassium channel independent of WNK4.

Cope G, Murthy M, Golbang AP, Hamad A, Liu CH, Cuthbert AW, O'Shaughnessy KM.

J Am Soc Nephrol. 2006 Jul;17(7):1867-74. Epub 2006 Jun 14.

40.

HapMap, pharmacogenomics, and the goal of personalized prescribing.

O'Shaughnessy KM.

Br J Clin Pharmacol. 2006 Jun;61(6):783-6. Review.

41.

Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals.

Yasmin, McEniery CM, O'Shaughnessy KM, Harnett P, Arshad A, Wallace S, Maki-Petaja K, McDonnell B, Ashby MJ, Brown J, Cockcroft JR, Wilkinson IB.

Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1799-805. Epub 2006 May 18.

PMID:
16709939
42.

Salt handling and hypertension.

O'Shaughnessy KM, Karet FE.

Annu Rev Nutr. 2006;26:343-65. Review.

PMID:
16602929
43.

Influence of fibrillin-1 genotype on aortic stiffness in men: a note of caution.

Yasmin, Wilkinson IB, O'Shaughnessy KM.

J Appl Physiol (1985). 2006 Apr;100(4):1431; author reply 1431-2. No abstract available.

44.

Genetic variation in fibrillin-1 gene is not associated with arterial stiffness in apparently healthy individuals.

Yasmin, O'Shaughnessy KM, McEniery CM, Cockcroft JR, Wilkinson IB.

J Hypertens. 2006 Mar;24(3):499-502.

PMID:
16467653
45.

Confirmation of a role for the 389R>G beta-1 adrenoceptor polymorphism on exercise capacity in heart failure.

Sandilands AJ, Parameshwar J, Large S, Brown MJ, O'Shaughnessy KM.

Heart. 2005 Dec;91(12):1613-4. No abstract available.

46.

The functional significance of genetic variation within the beta-adrenoceptor.

Sandilands AJ, O'Shaughnessy KM.

Br J Clin Pharmacol. 2005 Sep;60(3):235-43. Review.

47.

A new kindred with pseudohypoaldosteronism type II and a novel mutation (564D>H) in the acidic motif of the WNK4 gene.

Golbang AP, Murthy M, Hamad A, Liu CH, Cope G, Van't Hoff W, Cuthbert A, O'Shaughnessy KM.

Hypertension. 2005 Aug;46(2):295-300. Epub 2005 Jul 5.

PMID:
15998707
48.

WNK kinases and the control of blood pressure.

Cope G, Golbang A, O'Shaughnessy KM.

Pharmacol Ther. 2005 May;106(2):221-31. Epub 2005 Jan 26. Review.

PMID:
15866321
49.

Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success.

Hiby SE, Walker JJ, O'shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A.

J Exp Med. 2004 Oct 18;200(8):957-65. Epub 2004 Oct 11.

50.

Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms.

Sandilands A, Yeo G, Brown MJ, O'Shaughnessy KM.

Pharmacogenetics. 2004 Jun;14(6):343-9.

PMID:
15247626

Supplemental Content

Loading ...
Support Center